- Home
- TLPH vs IMRN Comparison
TLPH vs IMRN Comparison
Compare TLPH & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- IMRN
- Stock Information
- Founded
- TLPH 2005
- IMRN 1994
- Country
- TLPH United States
- IMRN Australia
- Employees
- TLPH N/A
- IMRN N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- IMRN Health Care
- Exchange
- TLPH Nasdaq
- IMRN Nasdaq
- Market Cap
- TLPH 12.7M
- IMRN 15.0M
- IPO Year
- TLPH 2011
- IMRN N/A
- Fundamental
- Price
- TLPH $0.51
- IMRN $2.01
- Analyst Decision
- TLPH Strong Buy
- IMRN Strong Buy
- Analyst Count
- TLPH 2
- IMRN 1
- Target Price
- TLPH $4.50
- IMRN $5.00
- AVG Volume (30 Days)
- TLPH 108.9K
- IMRN 5.7K
- Earning Date
- TLPH 11-13-2024
- IMRN 01-07-2025
- Dividend Yield
- TLPH N/A
- IMRN N/A
- EPS Growth
- TLPH N/A
- IMRN N/A
- EPS
- TLPH N/A
- IMRN N/A
- Revenue
- TLPH $281,000.00
- IMRN $3,271,194.00
- Revenue This Year
- TLPH N/A
- IMRN N/A
- Revenue Next Year
- TLPH N/A
- IMRN N/A
- P/E Ratio
- TLPH N/A
- IMRN N/A
- Revenue Growth
- TLPH N/A
- IMRN 171.67
- 52 Week Low
- TLPH $0.50
- IMRN $1.59
- 52 Week High
- TLPH $1.61
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- TLPH 29.73
- IMRN 49.93
- Support Level
- TLPH $0.64
- IMRN $1.86
- Resistance Level
- TLPH $0.69
- IMRN $2.23
- Average True Range (ATR)
- TLPH 0.06
- IMRN 0.14
- MACD
- TLPH -0.01
- IMRN -0.01
- Stochastic Oscillator
- TLPH 1.54
- IMRN 27.27
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.